What Bristol Laboratories does

Bristol Laboratories is a UK-based generic pharmaceutical company founded in 1997 and headquartered in Berkhamsted, Hertfordshire. The company develops, manufactures, markets and distributes a broad portfolio of generic prescription medicines spanning nine therapeutic areas — including CNS, cardiovascular, anti-diabetics, analgesics, anti-infectives, gastrointestinal, oncology, respiratory and urology — alongside a growing branded OTC consumer healthcare line (Allacan, Migraitan, RaniCalm, Ispagel Orange, LemoCalm, Zicron). Manufacturing is conducted at two UK sites in Luton and Peterlee, with combined capacity of up to 9 billion tablets and capsules annually, operated under MHRA regulation and GMP-compliant quality systems.

The company distributes its products primarily through national wholesale partners (including AAH and Alliance Healthcare) and directly to community pharmacies, retail pharmacy chains, and broader healthcare systems including the NHS. A dedicated Bristol Labs Consumer Care website supports consumer-facing OTC brand discovery. Sales are driven by field sales and business development teams, complemented by participation in industry events, pharmacy trade awards, and earned PR coverage.

Financially, Bristol Laboratories reported turnover of £90.4m and pre-tax profits of £8.7m for the year ended 31 March 2015, with growth from £66.8m the prior year. The privately held company, controlled by founder-Chairman T Ramachandran, has scaled headcount from 293 (2015) to over 600 (2016) — a doubling in approximately twelve months — and has received multiple Pharmacy Business Awards, signalling sustained commercial momentum. No external institutional investors, subsidiaries, or parent entities are identified in the data.

Name

Bristol Laboratories

Legal name

Bristol Laboratories Limited

Website

https://bristol-labs.co.uk

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Bristol Laboratories is a UK-based generic pharmaceutical company founded in 1997 that develops, manufactures and distributes prescription generics and branded OTC consumer healthcare products to pharmacies, wholesalers and the NHS across the UK and Europe.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

Keywords

• Generic pharmaceuticals
• Manufacturing medicines
• Consumer healthcare
• Generic drugs UK
• Tablet capsules production

Headquarters

HQ city

Berkhamsted

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Pharmaceuticals Sales: Sale of generic pharmaceutical products (prescription medicines) to pharmacies, healthcare providers, and through wholesale distribution. Revenue from POM (Prescription Only Medicines) and P (Pharmacy) category products.
2. OTC Consumer Healthcare Products: Sale of over-the-counter consumer healthcare products including Allacan, Migraitan, RaniCalm, Ispagel Orange through retail pharmacies and pharmacy chains.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Core offering

Bristol Laboratories develops, manufactures, markets, and distributes a broad portfolio of generic pharmaceutical products (POM, P, and GSL categories) across multiple therapeutic areas including CNS, cardiovascular, anti-diabetics, analgesics, anti-infectives, gastrointestinal, oncology, respiratory, and urology. The company also sells branded OTC consumer healthcare products such as Allacan, Migraitan, RaniCalm, Ispagel Orange, and LemoCalm Cold & Flu through pharmacy retail and wholesale distribution channels in the UK.

Product overview

Bristol Laboratories is a UK-based pharmaceutical company specializing in the development, manufacture, marketing, and distribution of generic medicines. The company operates as a single unified product portfolio of generic pharmaceuticals rather than a platform-plus-modules architecture. Their extensive portfolio spans multiple therapeutic areas including allergy and hayfever (Allacan, Cetirizine, Chlorphenamine), analgesics (Paracetamol, Ibuprofen, Codeine-based products, Tramadol, Sumatriptan/Migraitan), anti-diabetics (Gliclazide/Zicron, Metformin, Glimepiride), cardiovascular medications (Amlodipine, Atorvastatin, Ramipril, Losartan, various other antihypertensives), anti-infectives (antibiotics and antifungals), CNS medications (antidepressants, antiepileptics, antipsychotics, hypnotics, anti-Alzheimer's, anti-Parkinson's), gastrointestinal products (proton pump inhibitors, antiemetics, laxatives including Ispagel Orange), oncology drugs (Anastrozole, Letrozole, Bicalutamide), respiratory medications (Montelukast, Carbocisteine), and urology products (Sildenafil, Tadalafil, Finasteride). They also offer a consumer healthcare line featuring branded OTC products including Allacan for allergies, Migraitan for migraines, RaniCalm for heartburn, Ispagel Orange for constipation, and LemoCalm Cold & Flu products. Their manufacturing facilities can produce up to 9 billion tablets and capsules per year.

Differentiator

Problem solved

Functional benefit

Brands

• Allacan: Consumer healthcare brand for allergy and hayfever relief products
• Migraitan
• RaniCalm
• Zicron
• Ispagel
• LemoCalm
• Cetec

Products and services

• Allacan Branded OTC product providing fast and effective 24-hour relief from symptoms of hayfever and indoor allergies; available as Pharmacy (P) and General Sales List (GSL) products sold through retail pharmacies.
• Migraitan OTC sumatriptan-based migraine relief medication that targets migraine pain fast and begins relieving migraine headache within 30 minutes; pack size 2s sold through pharmacies.
• RaniCalm OTC ranitidine-based product offering up to 12 hours of fast-acting symptomatic relief from heartburn, acid indigestion and hyperacidity; pack size 12s sold through pharmacies.
• Ispagel Orange Bulk-forming laxative with concentrated natural fibre (ispaghula husk) in individual orange-flavoured sachets; used for relief of constipation including in pregnancy and for bowel function management in colostomy, ileostomy, haemorrhoids, anal fissure, chronic diarrhoea, IBS and ulcerative colitis.
• LemoCalm Cold & Flu Cold and flu relief powder combining paracetamol and phenylephrine for relief of sinus pain, congestion, and cold & flu symptoms; GSL product suitable for general sale.
• LemoCalm Max Flu Strength Maximum strength cold and flu relief powder with higher doses of paracetamol and phenylephrine for severe sinus pain, congestion, and cold & flu symptoms; GSL product.
• Zicron (Gliclazide) Branded generic sulfonylurea (gliclazide) anti-diabetic medication for type 2 diabetes management; prescription only medicine (POM).
• Paracetamol Tablets Generic analgesic and antipyretic paracetamol for pain and fever relief; available across multiple regulatory categories (POM, P, and GSL).
• Ibuprofen Tablets Generic NSAID ibuprofen for pain, inflammation and fever; available as POM, P, and GSL products.
• Metformin Tablets Generic first-line biguanide antidiabetic medication for type 2 diabetes management; prescription only medicine (POM).
• Amlodipine Tablets Generic calcium channel blocker amlodipine for hypertension and angina; prescription only medicine (POM).
• Atorvastatin Tablets Generic statin for hypercholesterolaemia and cardiovascular risk reduction; prescription only medicine (POM).
• Omeprazole Capsules Generic proton pump inhibitor omeprazole for gastric ulcer, duodenal ulcer and GORD; prescription only medicine (POM).
• Amoxicillin Capsules Generic penicillin antibiotic amoxicillin for bacterial infections; prescription only medicine (POM).
• Sertraline Tablets Generic SSRI antidepressant sertraline for depression and anxiety disorders; prescription only medicine (POM).
• Sildenafil Tablets Generic PDE5 inhibitor sildenafil for erectile dysfunction; prescription only medicine (POM).

Quantifiable outcome

• Revenue growth from £66.8m to £90.4m; operating profit growth from £6.6m to £8.8m; staff growth from 258 to 293

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• National Pharmacy AssociationminorGTM or Marketing Partner · 25 November 2016Pharmacy guide to Ispagel Orange with communication content approved by National Pharmacy Association for pharmacists and their teams.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Regional players

• Krka: Slovenian generic pharmaceutical manufacturer with established UK and European presence. Offers comparable horizontal generic portfolio across similar therapeutic categories, competing primarily on price for NHS tenders and pharmacy generics.

Broad incumbents

• Sandoz (Novartis): Global generics leader and Novartis division with extensive UK market presence across the same therapeutic categories as Bristol Laboratories. Provides broader portfolio and global scale advantages, but competes directly on NHS tenders and pharmacy generics supply.
• Viatris: Global healthcare company formed from Mylan-Upjohn merger with significant UK generics presence. Competes directly with Bristol Laboratories across cardiovascular, CNS, and other categories through NHS contracts and pharmacy wholesale channels.
• Teva UK: UK arm of global generics giant Teva Pharmaceutical Industries, supplying NHS and pharmacy channels with a broad portfolio overlapping Bristol's therapeutic categories. Offers scale advantages in manufacturing and global supply chain but is a direct competitor on key molecules.

Direct peers

• Wockhardt UK: UK-based generic and specialty pharmaceutical manufacturer with manufacturing facilities in UK and India. Competes directly with Bristol Laboratories on NHS generics supply and pharmacy wholesale across overlapping therapeutic portfolios.
• Ennogen Healthcare: UK-based generic pharmaceutical company supplying NHS and pharmacy channels with broad therapeutic portfolio. Direct mid-market competitor to Bristol Laboratories in UK generics distribution with similar scale and product breadth.
• Aurobindo Pharma UK: UK subsidiary of Indian generic manufacturer with strong NHS generics presence. Competes on price in commoditized molecules, leveraging lower cost manufacturing base against Bristol's UK-domestic production.
• Zentiva: European-focused generic pharmaceutical company with significant UK market presence, producing generic medicines across cardiovascular, CNS, and other therapeutic categories. Operates a similar horizontal generics portfolio model and competes for NHS and pharmacy contracts.
• Accord Healthcare: UK-headquartered generic pharmaceutical manufacturer owned by Intas Pharmaceuticals, producing generic medicines across multiple therapeutic categories with strong UK and European distribution through AAH and Alliance Healthcare. Directly competes with Bristol Laboratories on NHS tenders and pharmacy supply.

Emerging players

• Glenmark Pharmaceuticals Europe: India-headquartered generics manufacturer expanding UK and European footprint with respiratory, dermatology, and generic portfolios. Competes with Bristol on select molecules and OTC consumer healthcare categories.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/bristol.lab.ltd
• LinkedInlinkedin.com/company/bristol-laboratories-limited

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bristol Laboratories